X
[{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$31.3 million","upfrontCash":"Undisclosed","newsHeadline":"Orion Receives Total of EUR 28 Mllion Milestones From Bayer For Sales of Darolutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Orion Biotechnology"},{"orgOrder":0,"company":"Minakem (formerly Delmar Chemicals)","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$19.6 million","upfrontCash":"Undisclosed","newsHeadline":"DelMar Announces $19.6 Million Private Placement Priced at-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Minakem (formerly Delmar Chemicals)"},{"orgOrder":0,"company":"CanProbe","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Peptide","graph2":"CanProbe"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2\u2011Positive Gastroesophageal Adenocarcinoma (GEA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Zymeworks"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$430.0 million","upfrontCash":"$40.0 million","newsHeadline":"Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Zymeworks"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Zymeworks"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Zymeworks"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and Bayer Expand Development Program for Darolutamide in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Orion Biotechnology"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2\u2011Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Zymeworks"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Nymox Pharmaceutical"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Nymox Pharmaceutical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT\u2122 in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"BriaCell Therapeutics"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Reports New NYMOZARFEX Marketing Application is Accepted for Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Nymox Pharmaceutical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"BriaCell Therapeutics"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Vaccine","graph2":"BriaCell Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme, the 15-patient REM-001 confirmatory lead-in study and for working capital.
Lead Product(s):
Dianhydrogalactitol
Therapeutic Area: Oncology
Product Name: VAL-083
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $19.6 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
August 18, 2020
Details:
Bria-IMT (SV-BR-1-GM) is a genetically engineered human breast cancer cell line with features of immune cells. It is being evaluated in phase 3 clinical trials in combination with Zynyz (retifanlimab) for the treatment of advanced metastatic breast cancer.
Lead Product(s):
SV-BR-1-GM,Retifanlimab,Cyclophosphamide
Therapeutic Area: Oncology
Product Name: Bria-IMT
Highest Development Status: Phase III
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 07, 2024
Details:
Bria-IMT (SV-BR-1-GM) is an off-the-shelf targeted cellular immunotherapy. It is being evaluated in phase 3 clinical trials in combination with Zynyz (retifanlimab-dlwr) for the treatment of Metastatic breast cancer.
Lead Product(s):
SV-BR-1-GM,Cyclophosphamide ,Retifanlimab
Therapeutic Area: Oncology
Product Name: Bria-IMT
Highest Development Status: Phase III
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 20, 2023
Details:
Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostatic hyperplasia.
Lead Product(s):
Fexapotide triflutate
Therapeutic Area: Oncology
Product Name: Nymozarfex
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 26, 2023
Details:
Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy having both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.
Lead Product(s):
SV-BR-1-GM,Undisclosed
Therapeutic Area: Oncology
Product Name: Bria-IMT
Highest Development Status: Phase III
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 03, 2023
Details:
Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostatic hyperplasia.
Lead Product(s):
Fexapotide triflutate
Therapeutic Area: Oncology
Product Name: Nymozarfex
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 25, 2023
Details:
Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for low grade early prostate cancer.
Lead Product(s):
Fexapotide triflutate
Therapeutic Area: Oncology
Product Name: Nymozarfex
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 25, 2023
Details:
Study of ZW25 (zanidatamab) in combination with docetaxel results in 90.5% confirmed objective response rate (cORR) in first-line treatment of advanced HER2-positive breast cancer.
Lead Product(s):
Zanidatamab,Tislelizumab ,Capecitabine
Therapeutic Area: Oncology
Product Name: ZW25
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 26, 2022
Details:
Zymeworks' global Phase 3 study, HERIZON-GEA-01, which is investigating ZW25 (zanidatamab) in combination with chemotherapy plus or minus tislelizumab for first-line treatment of locally advanced, unresectable, or metastatic HER2-positive gastroesophageal adenocarcinoma.
Lead Product(s):
Zanidatamab,Capecitabine ,Oxaliplatin
Therapeutic Area: Oncology
Product Name: ZW25
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BeiGene
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 18, 2022
Details:
Zanidatamab, a HER2-targeted bispecific antibody, in combination with chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GJEC): Preliminary results from a Phase 1b/2 study.
Lead Product(s):
Zanidatamab,Capecitabine ,Oxaliplatin
Therapeutic Area: Oncology
Product Name: ZW25
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BeiGene
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 27, 2022